Company Overview
Modern expression-screening technologies (cDNA, CGH & Oligo arrays) have enabled the rapid identification of thousands of potential new biomarkers. TriStar High-density Prognosis Tissue Micro arrays can substantially accelerate their validation by the simultaneous screening of thousands of clinically well-defined tissue samples by Immunohistochemistry (IHC), Fluorescence in-situ hybridization (FISH) or RNA in-situ hybridization (ISH). Target expression/amplification is related to clinical data (prognosis, progression, drug treatment & response) in thousands of human normal and diseased tissues.
TriStar offers in-vitro and in-vivo screening of antibodies & small molecule compounds on the largest commercially available library of human cancer stem cells (CSCs). We offer contract research services as well as participate in joint development projects. CSCs represent a powerful tool for basic and translational researchers aimed at studying the pathogenic events that drive cancer initiation and progression, while providing crucial information for the development of therapeutic compounds targeting specific survival pathways of the tumorigenic population.
TriStar is based in Rockville, MD with repositories and scientific personnel located in Hamburg (Germany), Catania (Italy), Madrid (Spain) and Washington DC. Our library of over 60,000 micro-arrayed tissues is the largest of its kind in the world today. TriStar’s business model encompasses fee-for-service projects as well as providing standard and custom arrays to customers in Europe, Japan, Australia & USA. We are open to exploring collaborative opportunities for the co-development of interesting molecules.
New Arrays Click here for product lists
- Normal Tissue Array 96
- Multi Tumor Tissue Array 880
- Human Cancer Stem Cell (CSC) cytoinclusion array with matched CSC generated xenografts
- Breast cancers primary & paired distant metastases
- Triple negative breast cancer with follow up information
- Breast cancers with trastuzumab treatment data
- Breast cancer prognosis array 600
- Colon cancer progression array
- Colon cancer Stage II-III with KRAS data
- Colon cancer Stage IV with KRAS data
- Colon cancer with bevacizumab treatment information
- Colon cancer prognosis array
- Prostate cancer heterogeneity array
- Prostate cancer progression array 370
- Hormone refractory prostate cancers
- Prostate cancer prognosis array
- Small cell lung cancer (SCLC)
- Lung cancer prognosis array 400 with treatment information
- Pancreatic cancer primary & matched mets
- Multiple Myeloma 60
- Non-Hodgkin's Lymphoma High Grade 152
- Non-Hodgkin's Lymphoma Low Grade 71
32 normal human tissues, 3 donors each
50 donor samples each of lung adenocarcinoma,
lung squamous,lung undifferentiated,SCLC, breast lobular,
breast ductal, prostate, colon, NHL, head & neck, pancreatic, esophageal adenocarcinoma, esophageal squamous, bladder, kidney, melanoma mets, liver, ovarian
Cytospins of multiple human cancer stem cell lines of breast, colon, lung, glioblastoma & melanoma Xenografts generated from the same lines of breast, colon, lung & melanoma
35 primary tumors, 35 paired distant mets
Triple negative breast cancer with follow up information including treatment & response
40 breast cancers with follow up data including trastuzumab responders & non-responders
600 breast cancers with follow-up information
50 low grade adenoma, 50 high grade adenoma, 50 pT2, 50 pT3, 50 nodal mets, 50 liver mets, 10 normals
40 CRC with KRAS data, including mutations & wild type
40 CRC with KRAS data, including mutations & wild type
23 CRC with follow up information including bevacizumab treatment (metastatic & adjuvant) & response, 4 normals
300 colon cancers with follow-up information, with KRAS data incl mutations, treatment information
50 donors, one core each from 8 different primary tumor blocks per donor
Prostate cancer progression array 370 donors
50 HR prostate cancers
500 prostate cancers with 10 yr follow up information
30 donor samples SCLC
400 NSCLC with follow up information
30 pancreatic cancers with paired PT mets
60 multiple myeloma specimens
162 specimens of high grade NHL
69 specimens of low grade NHL